Mankind Pharma

Mankind Pharma Book Value per Share

The Book Value per Share of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 394.86 INR. In the previous year, Book Value per Share was 347.19 INR — a change of 13.73% (higher).

Book Value per Share

394.86INR

YoY

13.73%

Last updated:

Book Value per Share of Mankind Pharma is 2026 394.86 INR. Book Value per Share of Mankind Pharma was 2025 347.19 INR. It decreases by 13.73% higher compared to the previous year.

The Mankind Pharma Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2019
68.39 INR
Jan 1, 2020
84.43 INR
Jan 1, 2021
114.39 INR
Jan 1, 2022
149.11 INR
Jan 1, 2023
180.11 INR
Jan 1, 2024
226.81 INR
Jan 1, 2025
347.19 INR
Jan 1, 2026
394.86 INR
The Mankind Pharma Book Value per Share history
YEARBook Value per ShareYoY
394.86INR+13.73%
347.19INR+53.07%
226.81INR+25.93%
180.11INR+20.80%
149.11INR+30.35%
114.39INR+35.48%
84.43INR+23.46%
68.39INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Book Value per Share of Mankind Pharma is 394.86 INR in 2026.

Book Value per Share of Mankind Pharma changed from 347.19 INR to 394.86 INR, representing a 13.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mankind Pharma

All Key Metrics — Mankind Pharma